Results 41 to 50 of about 23,280 (257)

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

BMJ Open Diabetes Research & Care, 2020
Introduction Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population.Research design and methods We evaluated long-term
Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati   +9 more
doaj   +1 more source

Sitagliptin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in Aneurysm Necks Through the SDF-1/CXCR4/NRF2 Signaling Pathway

Frontiers in Endocrinology, 2019
Aneurysm (AN) embolization is an important treatment for cerebral aneurysms. The endothelialization of the aneurysm neck is crucial for preventing aneurysm recurrence.
Guo Yu, Guo Yu, Peixi Liu, Peixi Liu, Yuan Shi, Yuan Shi, Sichen Li, Sichen Li, Yingjun Liu, Yingjun Liu, Wei Zhu, Wei Zhu   +11 more
doaj   +1 more source

Real-world outcomes of sitagliptin and sitagliptin/metformin single-pill combination treatment in diverse type 2 diabetes populations (DIVERSITY study). [PDF]

Front Clin Diabetes Healthc
Introduction Real-world evidence on dipeptidyl peptidase-4 (DPP-4) inhibitors is limited by selective populations in randomized trials.
Janez A, Bojic M, Bozek T, Kamenov Z, Milenkovic T, Radulian G, Várkonyi T.   +6 more
europepmc   +2 more sources

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.

Diabetes & Metabolism, 2021
AIM Preclinical data suggest that treatment with either glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors could change the intestinal microbiome and thereby contribute to their beneficial (cardio)metabolic effects.
M. Smits, K. S. Fluitman, H. Herrema, M. Davids, M. Kramer, A. Groen, C. Belzer, W. D. de Vos, D. Cahen, Max Nieuwdorp, D. V. van Raalte   +10 more
semanticscholar   +1 more source

Sitagliptin Induces Tolerogenic Human Dendritic Cells [PDF]

, 2023
Sitagliptin, an anti-diabetic drug, is a dipeptidyl peptidase (DPP)-4/CD26 inhibitor with additional anti-inflammatory and immunomodulatory properties. In this study, we investigated for the first time the effect of sitagliptin on the differentiation and
Đokić, Jelena, Dejan Bokonjić, Drakul, Marija, Popović, Nikola, Bokonjić, Dejan, Marina Bekić, Tomić, Sergej, Jelena Đokić, Miloš Vasiljević, Rakočević, Sara, Vasiljević, Miloš, Dušan Mihajlović, Nikola Popović, Marija Drakul, Miodrag Čolić, Bekić, Marina, Sergej Tomić, Mihajlović, Dušan, Sara Rakočević, Čolić, Miodrag   +19 more
core   +1 more source

Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder

Oxidative Medicine and Cellular Longevity, 2022
Radiation‐induced intestinal injury is a common and critical complication of radiotherapy for pelvic or abdominal tumors, with limited therapeutic strategies and effectiveness.
Shan-Shan Huang, Yongbiao Huang, Wan-Syuan Lin, Lei Wang, Yang Yang, Piao Li, Lei Xiao, Yuan Chen, Q. Chu, Xianglin Yuan   +9 more
semanticscholar   +1 more source

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

Journal of the American Medical Association (JAMA), 2019
Importance Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1 receptor agonist, with other classes of glucose-lowering therapy.
J. Rosenstock, Dale C. Allison, Andreas L. Birkenfeld, T. Blicher, Srikanth Deenadayalan, J. Jacobsen, P. Serusclat, R. Violante, H. Watada, M. Davies   +9 more
semanticscholar   +1 more source

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

JAMA Network Open, 2022
Key Points Question What is the comparative risk of cardiovascular outcomes associated with empagliflozin vs liraglutide or sitagliptin, overall and across strata of age, sex, baseline atherosclerotic cardiovascular diseases, heart failure, and chronic ...
P. Htoo, Helen Tesfaye, S. Schneeweiss, D. Wexler, B. Everett, R. Glynn, Seoyoung C. Kim, M. Najafzadeh, L. Koeneman, S. F. Farsani, Anouk Déruaz-Luyet, Julie M. Paik, E. Patorno   +12 more
semanticscholar   +1 more source

Beneficial effects of sitagliptin ,metformin and their combination on myocardial ischemic and vascular changes in type-two diabetic rats [PDF]

Zagazig University Medical Journal, 2021
Background: Myocardial infarction is a critical complication frequently occurs with type2diabetes mellitus. Sitagliptin is antidiabetic drug inhibits DPP-4,which augments endogenous levels of GLP-1.Metformin is an FDA-approved antidiabetic drug, which ...
Kamal ElKashishy, Soad Kabil, Monira Khattab, Nabila Fahmy, Yassmen EL-sayed   +4 more
doaj   +1 more source

A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19

Journal of the Endocrine Society, 2022
Context COVID-19 may cause respiratory distress syndrome and death. Treatment of COVID-19 to prevent complications remains a priority. Objective Our investigation sought to determine whether combination of spironolactone and sitagliptin could reduce ...
F. Abbasi, R. Adatorwovor, M. Davarpanah, Y. Mansoori, M. Hajiani, Farzan Azodi, S. Sefidbakht, Shayesteh Davoudi, Farzana Rezaei, Shayan Mohammadmoradi, K. Asadipooya   +10 more
semanticscholar   +1 more source